ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 20.18% | 8.40% | 9.07% | 9.07% | -11.42% |
| Total Depreciation and Amortization | -74.28% | -0.70% | -8.04% | -8.04% | -9.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.01% | 52.98% | 207.01% | 207.01% | 140.18% |
| Change in Net Operating Assets | 886.21% | -103.34% | -37.39% | -37.39% | 81.28% |
| Cash from Operations | 49.29% | -66.99% | 5.00% | 5.00% | 9.05% |
| Capital Expenditure | -- | 19.75% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 19.75% | -98.44% | -98.44% | -- |
| Total Debt Issued | -18.23% | 694.00% | 377.75% | 377.75% | -- |
| Total Debt Repaid | 1.90% | 98.07% | -3.49% | -3.49% | 53.67% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -17.28% | 127.29% | 473.81% | 473.81% | 538.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.42% | 59.98% | 20.25% | 20.25% | 61.37% |